Reviewing Veracyte Inc. (VCYT)’s and Jaguar Health Inc. (NASDAQ:JAGX)’s results

This is therefore a comparing of the institutional ownership, profitability, analyst recommendations, risk, dividends, earnings and valuation in Veracyte Inc. (NASDAQ:VCYT) and Jaguar Health Inc. (NASDAQ:JAGX). The two are both Biotechnology companies that compete with one another.

Valuation and Earnings

Gross Revenue Price/Sales Ratio Net Income Earnings Per Share Price/Earnings Ratio
Veracyte Inc. 101.50M 13.03 15.74M -0.42 0.00
Jaguar Health Inc. 5.20M 49.24 33.76M -2.60 0.00

Demonstrates Veracyte Inc. and Jaguar Health Inc. earnings per share, gross revenue and valuation.

Profitability

Table 2 hightlights the return on equity, net margins and return on assets of the two companies.

Net Margins Return on Equity Return on Assets
Veracyte Inc. -15.51% -23.4% -14.7%
Jaguar Health Inc. -649.23% -253.4% -70%

Volatility & Risk

Veracyte Inc. has a 0.93 beta, while its volatility is 7.00% which is less volatile than Standard & Poor’s 500. Competitively, Jaguar Health Inc.’s beta is 1.18 which is 18.00% more volatile than Standard & Poor’s 500.

Liquidity

The Current Ratio and a Quick Ratio of Veracyte Inc. are 6.3 and 6.1. Competitively, Jaguar Health Inc. has 0.3 and 0.2 for Current and Quick Ratio. Veracyte Inc.’s better ability to pay short and long-term obligations than Jaguar Health Inc.

Analyst Recommendations

The table shown features the ratings and recommendations for Veracyte Inc. and Jaguar Health Inc.

Sell Ratings Hold Ratings Buy Ratings Rating Score
Veracyte Inc. 0 0 1 3.00
Jaguar Health Inc. 0 0 0 0.00

$23 is Veracyte Inc.’s average price target while its potential downside is -16.58%.

Institutional & Insider Ownership

Roughly 85.5% of Veracyte Inc. shares are held by institutional investors while 12.6% of Jaguar Health Inc. are owned by institutional investors. Insiders held 0.5% of Veracyte Inc. shares. Insiders Comparatively, held 13.23% of Jaguar Health Inc. shares.

Performance

Here are the Weekly, Monthly, Quarterly, Half Yearly, Yearly and YTD Performance of both pretenders.

Performance (W) Performance (M) Performance (Q) Performance (HY) Performance (Y) Performance (YTD)
Veracyte Inc. 4.28% -0.12% 34.48% 69.96% 276.88% 95.63%
Jaguar Health Inc. -14.17% -22.47% -28.13% -62.9% -92.77% -24.61%

For the past year Veracyte Inc. has 95.63% stronger performance while Jaguar Health Inc. has -24.61% weaker performance.

Summary

Veracyte Inc. beats on 10 of the 11 factors Jaguar Health Inc.

Veracyte, Inc. operates as a molecular diagnostics company in the United States. The company uses genomic technology to resolve diagnostic ambiguity. It offers Afirma Thyroid FNA Analysis solution for use in thyroid cancer diagnosis; cytopathology testing services; and the Afirma Malignancy Classifiers to manage thyroid nodule patients. The companyÂ’s products also include Percepta Bronchial Genomic Classifier solution for use in lung cancer screening and diagnosis; and Envisia Genomic Classifier solution for idiopathic pulmonary fibrosis. It sells its products through its product specialists, institutional channel managers, account managers, and clinical science specialists. The company was formerly known as Calderome, Inc. and changed its name to Veracyte, Inc. in March 2008. Veracyte, Inc. was incorporated in 2006 and is headquartered in South San Francisco, California.

Napo Pharmaceuticals, Inc., a human health company, focuses on developing and commercializing novel gastrointestinal prescription products from plants. Its products include Mytesi, an FDA approved product for the symptomatic relief of noninfectious diarrhea in adults with HIV/AIDS on antiretroviral therapy. Napo Pharmaceuticals, Inc. was formerly known as PS Pharmaceuticals, Inc. The company was founded in 2001 and is based in San Francisco, California.

Receive News & Ratings Via Email - Enter your email address below to receive a concise daily summary of the latest news and analysts' ratings with our FREE daily email newsletter.